TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1549-1556

  Barbisan, Gisela ^a   Pérez, Luis Orlando ^a   Contreras, Anahí ^a   Golijow, Carlos Daniel ^a  

^a Universidad Nacional de La Plata   (Argentina)

Author keywords

Cervical cancer; HPV; IL 10; Polymorphisms; TNF

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 10 GENE; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TNF ALPHA GENE; UTERINE CERVIX CANCER;

EID: 84868141469     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0408-1     Document Type: Article

References (48)

1. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer (2005). Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
3. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
4. Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: is there a hereditary component? Int J Cancer. 1999;82:775-81.
5. Horng JT, Hu KC, Wu LC, et al. Identifying the combination of genetic factors that determine susceptibility to cervical cancer. IEEE Trans Inf Technol Biomed. 2004;8:59-66.
6. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50.
7. Kadish AS, Ho GY, Burk RD, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst. 1997;89:1285-93.
8. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997;89:245-50.
9. Tartour E, Gey A, Sastsre-Garou X, Lombard Surin I, Mosseri V, Fridman WH. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst. 1998;90:287-94.
10. Tartour E, Pannetier C, Mathiot C, et al. Prognostic value of cytokine and Fc gamma receptor assays in oncology. Immunol Lett. 1995;44:145-8.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;38:423-8.
12. Li H, Groop L, Nilsson A, Weng J, Tuomi T. A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes. J Clin Endocr Metab. 2003;88:2767-74.
13. Pillai S, Bikle DD, Eessalu TE, Aggarwal BB, Elias PM. Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes. J Clin Invest. 1989;83:816-21.
14. Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barretts metaplasia and cancer: a unique role for TNF alpha. Eur J Cancer Prev. 2001;10:163-6.
15. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391-9.
16. Wilson AG, Symons JA, McDowell TL, McDevitt HQ, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195-9.
17. Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol. 1998;54:173-7.
18. Jang WH, Yang YI, Yea SS, et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41-6.
19. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21:S447-63.
20. Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastasic disease. J Biol Regul Homeost Agents. 1992;6:103-7.
21. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
22. Alamartine E, Berthoux P, Mariat C, Cambazard F, Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Derm. 2003;120:99-103.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
24. Ting Y, Manos MM. Detection and typing of genital human Papillomavirus. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols. San Diego: Academic Pres; 1990. p. 356.
25. Evander M, Edlund K, Bodun E, et al. Comparison of a one-step and two-step polimerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol. 1992;30:987-92.
26. Söderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol. 2005;43:3260-6.
27. Stanczuk GA, Sibanda EN, Perrey C, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94:792-4.
28. Deshpande A, Nolan JP, White PS, et al. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005;191:969-76.
29. Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNF alpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol. 2004;92:675-9.
30. Liu L, Yang X, Chen X, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2683-8.
31. Badano I, Stietz SM, Schurr TG, et al. Analysis of TNF-α promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol. 2012;53:54-9.
32. Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006;6:24.
33. Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:148-53.
34. Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116:544-8.
35. Calhoun ES, McGovern RM, Janney CA, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218-24.
36. Magalhães RF, Biral AC, Pancoto JA, et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol. 2010;49:1133-40.
37. Nedoszytko B, Szczerkowska-Dobosz A, Zabłotna M, Gleń J, Rebała K, Roszkiewicz J. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol. 2007;157:165-7.
38. Gostout BS, Poland GA, Calhoun ES, et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol. 2003;88:326-32.
39. Fong CL, Siddiqui AH, Mark DF. Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res. 1994;22:1108-14.
40. kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol. 2000;114:1180-3.
41. Matsumoto K, Oki A, Satoh T, et al. Interleukin-10-1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 2010;40:1113-6.
42. Zoodsma M, Nolte IM, Schipper M, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005;15:282-90.
43. Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J Carcinog. 2003;2:3.
44. Szöke K, Szalmás A, Szládek G, et al. IL-10 promoter nt -1082A/G polymorphism and human papillomavirus infection in cytologic abnormalities of the uterine cervix. J Interferon Cytokine Res. 2004;24:245-51.
45. Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet. 2000;27:241-9.
46. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998;6:193-7.
47. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1090-5.
48. Poli F, Nocco A, Berra S, et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet. 2002;29:237-40.